Kyowa Kirin urges NICE to reconsider following Crysvita snub

29 November 2023
kyowa-big-1

The National Institute for Health and Care Excellence (NICE) has opted against recommending Crysvita (burosumab) to treat adults in England and Wales who have a confirmed diagnosis of X-linked hypophosphataemia (XLH).

Drug developer Kyowa Kirin (TYO: 4151) has expressed disappointment at NICE’s decision, outlined in its initial Appraisal Consultation Document (ACD), but said that the company remains committed to finding a solution for adults living with XLH to have access to the medicine, and vowed to continue working with the NICE, NHS England and others to find a resolution.

"We fully support the UK Rare Disease Framework and specifically priority four - improving access to specialist care, treatments and drugs"Kyowa Kirin warned that the decision would create a disparity in access between England and Wales on the one hand, and Scotland on the other.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology